Pharmascience Inc. Acquires Aegera Therapeutics; Aegera's Employees to Retain Their Jobs
5/27/2011 6:35:25 AM
More...
|
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
1/26/2010 9:45:13 AM
More...
|
Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors
11/23/2009 10:04:55 AM
More...
|
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
11/19/2009 8:52:38 AM
More...
|
Aegera Therapeutics Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile
11/16/2009 8:52:53 AM
More...
|
Aegera Therapeutics Closes CDN $7 Million Financing
9/23/2009 10:57:37 AM
More...
|
Aegera Therapeutics Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
5/6/2009 11:32:55 AM
More...
|
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
1/8/2009 10:33:48 AM
More...
|
Aegera Therapeutics Phase 1/2 Clinical Trial Results Selected for Oral Presentation at 2008 American Society of Hematology Annual Meeting
11/25/2008 9:29:39 AM
More...
|
Neurologix, Inc. Licenses Exclusive Rights to Key Gene from Aegera Therapeutics for Use as a Potential Gene Therapy for Huntington's Disease
9/3/2008 6:06:48 AM
More...
|
|